Skip to content
AlternativeMed

Immune Responses to Gene Therapy and Delivery Vehicles

How the immune system reacts to viral vectors and lipid carriers, what FDA labels say about antibody screening, liver and muscle inflammation, and why immune reactions limit repeat dosing.

Content last updated . This page has not been medically reviewed.

Quick answer
The body treats a gene therapy carrier much as it treats any foreign particle. Immune reactions can lower how well a product works, cause serious side effects, and often prevent a second dose. This is a safety and design problem for researchers, not something a person can adjust with supplements.

Historical lessons

The researcher who led an early liver gene therapy trial later published a reflection on it, after a research participant died from complications of vector administration; he writes that the death provoked a series of events with implications beyond the trial. [9] In another early trial, retrovirus vector insertion led to abnormal T-cell growth in two patients. [10] These are old events, but they explain why current labels and FDA guidance stress monitoring. The FDA's long-term follow-up guidance notes that people exposed to investigational gene therapy products may face increased risk of unpredictable delayed adverse events. [11] See Off-Target Effects, Durability and Long-Term Monitoring.

Lipid carriers and immune reactions

LNPs are not viruses, but they can still provoke responses. A review describes anti-PEG antibody production and complement activation as pathways linked to PEG lipids. [12] In ONPATTRO studies, antibodies to a PEG lipid on the particle surface were measured and the label lists infusion-related reactions among its warnings. [13] A mouse study found that circulating anti-PEG IgM reduced liver protein production from an mRNA-LNP; that is preclinical. [14] See Lipid Nanoparticles and Non-Viral Delivery.

What this does not show

  • It does not show that these products fail. It shows that the immune system is a central safety and design issue.
  • It does not support the idea that people can prevent such reactions by supplements or "immune support." No source read for this page tested that.
  • Findings in healthy mice do not predict people's reactions. See Cell Studies vs Animal Studies vs Human Trials.

Frequently asked questions

Why is a gene therapy usually given only once?

Labels for AAV products describe antibodies that form after treatment and note that repeat administration has not been evaluated for ZOLGENSMA. [8][6]

Why do some people get tested before treatment?

Pre-existing antibodies to the vector can block it. Some indications and labels require antibody testing or the absence of such antibodies. [4][7]

Do immune reactions mean the therapy is unsafe?

They mean monitoring matters. Labels list liver, heart and muscle problems for some products. [7] In the LUXTURNA phase 3 trial, no deleterious immune responses were reported among treated participants, though that trial was small. [15]

Can I protect myself with immune supplements?

Nothing read for this page supports that. Ask the treating team about any supplement or medicine. See Talking With a Health Professional.

More details: evidence, limits and cautions

The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.

How to read the evidence labels

Labels used on this page: approved medicine, established, preclinical (cells/animals only), insufficient evidence. For immune basics, see Innate and Adaptive Immunity.

What reviews say

A 2020 review states that innate and adaptive immune responses to viral vectors and their transgene products are substantial hurdles to clinical development and wider use. [1] A 2013 review in Blood noted that because AAV vectors are given directly to patients, the likelihood of a host immune response is high, and that responses to the wild-type virus or to the gene product can interfere with effectiveness if not identified and managed. [2] For hemophilia, a 2021 review says both innate and adaptive responses can affect safety and efficacy. [3] These are reviews, so they summarize earlier studies and do not give new effect sizes.

Antibodies that already exist

Many people have antibodies from earlier exposure to natural AAV viruses. These can block a vector. FDA materials show how products handle this:
  • ROCTAVIAN is indicated for adults with severe hemophilia A without pre-existing antibodies to AAV serotype 5, detected by an FDA-approved test. [4]
  • BEQVEZ (hemophilia B) lists absence of neutralizing antibodies to its AAV capsid, detected by an FDA-approved test, as part of the indication. [5]
  • ZOLGENSMA and ELEVIDYS labels instruct baseline testing for antibodies to their vector types (anti-AAV9 and anti-AAVrh74). [6][7]
  • The HEMGENIX label says preexisting neutralizing anti-AAV antibodies may impede expression of the gene at desired levels. [8]

Antibodies that form afterward

After HEMGENIX treatment, the label says all patients developed neutralizing antibodies to the AAV5 capsid. [8] The ZOLGENSMA label states that the safety and effectiveness of repeat administration have not been evaluated. [6] In plain terms, many single-dose gene therapies are designed as one-time treatments partly because the first dose can make a second one unlikely to work. This is an interpretation of the labels, not a statement either label makes.

Immune-related side effects named in labels

Table of examples from US FDA labels (not a full list):
ProductImmune-related issue the label describes
ZOLGENSMAAcute liver failure with fatal outcomes; a warning for thrombotic microangiopathy (a blood-clotting and kidney problem) [6]
ELEVIDYSAcute serious liver injury and failure; life-threatening myocarditis (heart inflammation); severe immune-mediated myositis (muscle inflammation) [7]
HEMGENIXImmune-mediated neutralization of the vector capsid, in addition to liver and infusion-reaction warnings [8]

Steroids and other immune-suppressing medicines are part of these regimens. The ZOLGENSMA label instructs systemic corticosteroid before and after infusion [6], and the ELEVIDYS label warns that serious infections with fatal outcomes may occur due to concomitant corticosteroids, additional immunosuppressants and the product. [7] This shows the trade-off: dampening the immune response can protect the liver and cost protection against infection. Treatment decisions belong with the specialist team.

Safety note
Anyone who has received a gene therapy product and notices new or worsening symptoms, such as unexplained muscle pain, tenderness or weakness (named in the ELEVIDYS label), should contact the treating team promptly; in an emergency call 911 (US) or local emergency services. Never stop or change prescribed medicines, including steroids, without the prescriber.
References
  1. Shirley JL et al. Immune responses to viral gene therapy vectors. Mol Ther 2020. PubMed 31968213. Read 2026-10-22.
  2. Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 2013. PubMed 23596044. Read 2026-10-22.
  3. Monahan PE et al. Emerging immunogenicity and genotoxicity considerations of adeno-associated virus vector gene therapy for hemophilia. J Clin Med 2021. PubMed 34199563. Read 2026-10-22.
  4. US FDA, ROCTAVIAN product page. Read 2026-10-22.
  5. US FDA, BEQVEZ product page. Read 2026-10-22.
  6. US FDA prescribing information, ZOLGENSMA (label data via openFDA). Read 2026-10-22.
  7. US FDA prescribing information, ELEVIDYS (label data via openFDA). Read 2026-10-22.
  8. US FDA prescribing information, HEMGENIX (label data via openFDA). Read 2026-10-22.
  9. Wilson JM. Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab 2009. PubMed 19211285. Read 2026-10-22.
  10. Hacein-Bey-Abina S et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003. PubMed 14564000. Read 2026-10-22.
  11. US FDA, Long Term Follow-Up After Administration of Human Gene Therapy Products (guidance). Read 2026-10-22.
  12. Gao P et al. PEGylated lipids in lipid nanoparticle delivery dynamics and therapeutic innovation. Beilstein J Nanotechnol 2025. PubMed 41189930. Read 2026-10-22.
  13. US FDA prescribing information, ONPATTRO (label data via openFDA). Read 2026-10-22.
  14. Abe S et al. Impact of pre-existing anti-polyethylene glycol (PEG) IgM on biodistribution and humoral response of intramuscularly administered PEGylated mRNA loaded lipid nanoparticle. J Control Release 2025. PubMed 40339658. Read 2026-10-22.
  15. Russell S et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 2017. PubMed 28712537. Read 2026-10-22.
Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.